Özakbaş, S. Et Al. 2022. Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up. ECTRIMS 2022 , (Amsterdam, Netherlands), 862.

Özakbaş, S., Baba, C., Kaya, E., Özçelik, S., Özdoğar, A. T., & Daştan, S., (2022). Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up . ECTRIMS 2022 (pp.862). Amsterdam, Netherlands

Özakbaş, SERKAN Et Al. "Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up," ECTRIMS 2022, Amsterdam, Netherlands, 2022

Özakbaş, SERKAN Et Al. "Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up." ECTRIMS 2022 , Amsterdam, Netherlands, pp.862, 2022

Özakbaş, S. Et Al. (2022) . "Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up." ECTRIMS 2022 , Amsterdam, Netherlands, p.862.

@conferencepaper{conferencepaper, author={SERKAN ÖZAKBAŞ Et Al. }, title={Effects of ocrelizumab on disability progression and inflammatory activity in multiple sclerosis patients during the two-year follow-up}, congress name={ECTRIMS 2022}, city={Amsterdam}, country={Netherlands}, year={2022}, pages={862} }